

Amendment to the Claims

1. (Currently amended) A method of modulating differentiation or neoplastic transformation of cells ~~by causing~~ comprising the step of administering a cad-11 antisense or sense oligonucleotide to said cells to increase or decrease cad-11 expression or function.
2. (Withdrawn) The method of claim 1 wherein said modulation is of differentiation or neoplastic transformation of the cell.
3. (Original) The method of claim 1 wherein said modulation is for preventing or terminating a pregnancy, and said method comprises decreasing cad-11 function or expression in trophoblast cells.
4. (Original) The method of claim 1 wherein said modulation is for reducing the viability of carcinoma cells having a low to moderate metastatic potential, and said method comprises decreasing cad-11 expression or function in the cells.
5. (Withdrawn) The method of any one of claims 1-4, wherein cad-11 expression is increased by hormone treatment of the cells.
6. (Withdrawn) The method of any one of claims 1-4, wherein cad-11 function is decreased by contacting the cells with an agent that interferes with cad-11 function.
7. (Withdrawn) The method of claim 6 wherein said agent is an anti-cad-11 antibody.
8. (Cancelled)

9. (Currently amended) The method of claims 1, 3 or 4 wherein said **agent** oligonucleotide prevents transcription to or translation of, cad-11 mRNA.

10. (Currently amended) The method of claim 9 wherein said agent is an antisense oligonucleotide.

11. (Currently amended) The method of claim 1 ~~40~~ wherein said oligonucleotide comprises an oligonucleotide substantially identical to, or which will hybridize to SEQ ID NO:1 or SEQ ID NO:2.

12. (Original) The method of claim 4 wherein said carcinoma cells are prostate tumor cells.

13. (Withdrawn) The use of a hormone for preparation of a medicament for use in the method of any one of claims 1-12.

14. (Withdrawn) The use of an agent that interferes with cad-11 function for preparation of a medicament for use in the method of any one of claims 1-12.

15. (Withdrawn) The use according to claim 14 wherein said agent is an anti-cad-11 antibody.

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Withdrawn) A method for assessing the metastatic potential of carcinoma cells comprising: contacting cells in a tissue sample suspected of containing a carcinoma with a detectable indicator capable of binding to cad-11 or cad-11 mRNA; and, determining the presence or absence of cad-11 expression in the tissue.

20. (Withdrawn) The method of claim 19 wherein said detectable indicator comprises an oligonucleotide.

21. (New) The method of claim 1 wherein the cad-11 oligonucleotide comprises nucleotides of SEQ ID NO: 5 or the complementary sequence thereto.

22. (New) The method of claim 1 wherein the cad-11 oligonucleotide comprises 7-50 bases.

23. (New) The method of claim 1 wherein the cad-11 oligonucleotide comprises at least about 15 bases.

24. (New) The method of claim 21 wherein the cad-11 oligonucleotide comprises 13-20 bases.

Amendment to the Sequence Listing

Replace the sequence listing pages 1-2 originally filed in the application with the substitute sequence listing pages 1-7 submitted herewith.